Non-IgG Therapeutic Antibody Development

Question: Why are non-IgG isotypes emerging as potent alternatives in next-generation antibody therapy?

Answer: While IgG is the industry standard, isotypes like IgA and IgM offer distinct therapeutic benefits, including higher avidity and the ability to operate effectively at mucosal surfaces. Utilizing therapeutic non-IgG antibody engineering services enables the design of innovative biologics that can engage specific Fc receptors, such as FcαRI on neutrophils, providing a powerful mechanism for tumor cell killing and pathogen neutralization in diverse disease models.